An investigation for investors in NYSEMKT:TRXC shares was announced over potential breaches of fiduciary duties by certain officers and directors at Transenterix.
Shares of Transenterix Inc NYSEMKT:TRXC) declined to a slow as $1.03 per share on June 27, 2016.
Investors who purchased shares of Transenterix Inc (NYSEMKT:TRXC) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Transenterix officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On April 20, 2016, Transenterix Inc announced that the Food and Drug Administration (“FDA”) notified Transenterix Inc on April 19, 2016 of its determination that the “SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission.”
Those who purchased NYSEMKT:TRXC shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego